Injectable in situ forming microparticles: A novel drug delivery system
dc.citation.epage | 318 | en_US |
dc.citation.issueNumber | 2 | en_US |
dc.citation.spage | 307 | en_US |
dc.citation.volumeNumber | 11 | en_US |
dc.contributor.author | Yapar, E. A. | en_US |
dc.contributor.author | Inal, Ö. | en_US |
dc.contributor.author | Özkan, Y. | en_US |
dc.contributor.author | Baykara, T. | en_US |
dc.date.accessioned | 2018-04-12T13:53:36Z | |
dc.date.available | 2018-04-12T13:53:36Z | |
dc.date.issued | 2012 | en_US |
dc.department | Institute of Materials Science and Nanotechnology (UNAM) | en_US |
dc.description.abstract | Pharmaceutical formulation research has recently been focusing on delivery systems which provide long therapeutic effects and reduced side effects, and involving simplified production stages and facilitated application process. In situ forming microparticle (ISM) systems, one of the latest approach in this field, offer a new encapsulation technique and meet the objectives stated above. Factors such as the carrier used to form the multiparticles, amount and type of drug and the vehicle type can be taken as the main performance criteria for these systems. Ongoing studies have shown that this new multiparticulate drug delivery system is suitable for achieving new implant delivery system with low risk of dose-dumping, capable of being modulated to exhibit varying release patterns, reproducible, easily applicable and welltolerated compared with classically surgical implants. | en_US |
dc.description.provenance | Made available in DSpace on 2018-04-12T13:53:36Z (GMT). No. of bitstreams: 1 bilkent-research-paper.pdf: 179475 bytes, checksum: ea0bedeb05ac9ccfb983c327e155f0c2 (MD5) Previous issue date: 2012 | en |
dc.identifier.doi | 10.4314/tjpr.v11i2.19 | en_US |
dc.identifier.eissn | 1596-9827 | en_US |
dc.identifier.issn | 1596-5996 | |
dc.identifier.uri | http://hdl.handle.net/11693/38340 | |
dc.language.iso | English | en_US |
dc.relation.isversionof | http://dx.doi.org/10.4314/tjpr.v11i2.19 | en_US |
dc.source.title | Tropical Journal of Pharmaceutical Research | en_US |
dc.subject | Controlled drug delivery | en_US |
dc.subject | In situ forming | en_US |
dc.subject | Injectable | en_US |
dc.subject | Microparticle system | en_US |
dc.subject | Bupivacaine | en_US |
dc.subject | Diltiazem | en_US |
dc.subject | Haloperidol | en_US |
dc.subject | Leuprorelin | en_US |
dc.subject | Microsphere | en_US |
dc.subject | Montelukast | en_US |
dc.subject | Oil | en_US |
dc.subject | Risperidone | en_US |
dc.subject | Clinical effectiveness | en_US |
dc.subject | Concentration (parameters) | en_US |
dc.subject | Controlled drug release | en_US |
dc.subject | Drug blood level | en_US |
dc.subject | Drug delivery system | en_US |
dc.subject | Drug efficacy | en_US |
dc.subject | Drug formulation | en_US |
dc.subject | Drug solubility | en_US |
dc.subject | Drug stability | en_US |
dc.subject | Drug synthesis | en_US |
dc.subject | Drug tolerability | en_US |
dc.subject | Human | en_US |
dc.subject | Hydrophilicity | en_US |
dc.subject | Hydrophobicity | en_US |
dc.subject | In vitro study | en_US |
dc.subject | In vivo study | en_US |
dc.subject | Maximum plasma concentration | en_US |
dc.subject | Microencapsulation | en_US |
dc.subject | Nonhuman | en_US |
dc.subject | Particle size | en_US |
dc.subject | Phase separation | en_US |
dc.subject | Process development | en_US |
dc.subject | Reproducibility | en_US |
dc.subject | Review | en_US |
dc.subject | Surface property | en_US |
dc.subject | Toxicity testing | en_US |
dc.title | Injectable in situ forming microparticles: A novel drug delivery system | en_US |
dc.type | Review | en_US |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- Injectable In Situ Forming Microparticles A Novel.pdf
- Size:
- 443.48 KB
- Format:
- Adobe Portable Document Format
- Description:
- Full printable version